Frontiers journals are at the top of citation and impact metrics
Dramatic progresses have been made in the field of tumor immunology and immunotherapies during the preceding 15 years.
The clinical impact associated with the tumor immune infiltrate, the impressive clinical activities of monoclonal antibodies modulating the immune microenvironment or directed to tumor cells, the successes of engineered T cells therapies and the development of cancer vaccines against mutated tumor antigens demonstrate that the immune system can be a powerful ally against cancer.
The section’s ambitions are to drive the rapidly moving field of immunosurveillance, tumor escape and immunotherapy by hosting primary research, discussions, reviews, conflicting positions and novel hypotheses.
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Cancer Immunity and Immunotherapy welcomes submissions of the following article types: Case Report, Classification, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Protocols, Review, Systematic Review and Technology Report.
All manuscripts must be submitted directly to the section Cancer Immunity and Immunotherapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cancer Immunity and Immunotherapy will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Immunology and Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com